Development of high accuracy multidrug resistance prediction method using SPECT imaging for individualized anticancer therapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09949
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kanazawa University
• Principal Investigator: KOBAYASHI Masato 金沢大学, 健康増進科学センター, 助教 (30444235)
• Co-Investigator(Kenkyū-buntansha): 川井 恵一 金沢大学, 保健学系, 教授 (30204663)
• Co-Investigator(Renkei-kenkyūsha): TAMAI Ikumi 金沢大学, 薬学系, 教授 (20155237) ; OKAZAWA Hidehiko 福井大学, 高エネルギー医学研究センター, 教授 (50360813) ; KUNISHIMA Munetaka 金沢大学, 薬学系, 教授 (10214975) ; NISHII Ryuichi 放射線医学総合研究所, 分子イメージング診断治療研究部, 主任研究員 (60463212) ; SHIKANO Naoto 茨城県立医療大学, 保健医療学部, 准教授 (80295435) ; NISHI Kodai 長崎大学, 原爆後障害医療研究所, 助教 (10719496)
• Research Collaborator: INNIS B Robert National Institute of Mental Health, Molecular Imaging Branch, Chief
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 核医学 / 分子イメージング / 個別化治療 / 多剤耐性 / 薬物トランスポータ

Outline of Final Research Achievements

We developed high an accuracy multidrug resistance prediction method using SPECT imaging for individualized anticancer therapy. Although [99mTc]sestamibi and [99mTc]tetrofosmin has been reported to be the same method, we clarified that [99mTc]sestamibi had affinity to MDR1 and MRP1, whereas [99mTc]tetrofosmin had affinity to MDR1 and MRP1-3. Thus, these SPECT tracers had different method for multidrug resistance prediction in this study. Additionally, [131I]adsterol was possibility to be higher accuracy multidrug resistance prediction method than [99mTc]sestamibi and [99mTc]tetrofosmin because [131I]adsterol had only affinity to BCRP.

Free Research Field

放射線科学